Page last updated: 2024-12-07

hydroxycotinine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Hydroxycotinine is a major metabolite of nicotine, formed in the liver by the enzyme cytochrome P450 2A6. It is found in the blood, urine, and saliva of smokers. Hydroxycotinine is a more stable metabolite of nicotine than cotinine, and its levels are often used as a biomarker of tobacco smoke exposure. Research has shown that hydroxycotinine is associated with an increased risk of cardiovascular disease, cancer, and other health problems. It is also studied for its potential therapeutic effects, such as its ability to protect against neurotoxicity. Hydroxycotinine is often used in research to assess the effectiveness of smoking cessation interventions. '

hydroxycotinine: metabolite of nicotine; RN given refers to (S)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

trans-3-hydroxycotinine : An N-alkylpyrrolidine that is cotinine substituted at position C-3 by a hydroxy group (the 3R,5S-diastereomer). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID107963
CHEMBL ID1614639
CHEBI ID71182
SCHEMBL ID10893109
MeSH IDM0041542

Synonyms (33)

Synonym
hydroxycotinine
3-hydroxy-1-methyl-5-(3-pyridinyl)-2-pyrrolidinone
ccris 7628
trans-3'-hydroxycotinine
3'-hydroxycotinine
trans-3'-hydroxy cotinine
1-methyl-3-hydroxy-5-(3-pyridyl)-2-pyrrolidinone
(3r,5s)-3-hydroxy-1-methyl-5-pyridin-3-ylpyrrolidin-2-one
2-pyrrolidinone, 3-hydroxy-1-methyl-5-(3-pyridinyl)-, (3r,5s)-
108450-02-8
chebi:71182 ,
CHEMBL1614639
h7lh47y29a ,
34834-67-8
unii-h7lh47y29a
(3r-trans)-3-hydroxy-1-methyl-5-(3-pyridinyl)-2-pyrrolidinone
(3r,5s)-3-hydroxy-1-methyl-5-(pyridin-3-yl)pyrrolidin-2-one
trans-3-hydroxycotinine
SCHEMBL10893109
W-202428
3-hydroxy-1-methyl-5-pyridin-3-yl-pyrrolidin-2-one
3-hydroxy-1-methyl-5-(3-pyridinyl)-2-pyrrolidinone #
AKOS027384171
1-methyl-3-(r)-hydroxy-5-(s)-3-pyridyl-2-pyrrolidinone
223655-46-7
CS-0059384
HY-113239
3'-hydroxycotinine, trans-
DTXSID30873224
Q27139424
MS-23039
trans-3-hydroxy-1-methyl-5-(pyridin-3-yl)pyrrolidin-2-one
hydroxycotinine; aif; ce0; ms2dec

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" However, other compounds metabolized by CYP2A6, as well as other drugs excreted via renal clearance mechanisms similar to those of nicotine, may be susceptible to significant pharmacokinetic grapefruit juice interactions."( Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance.
Benowitz, NL; Hukkanen, J; Jacob, P, 2006
)
0.33
" A mechanistic population pharmacokinetic model was fitted to all data simultaneously."( Population pharmacokinetics of nicotine and its metabolites I. Model development.
Benowitz, NL; Dempsey, DA; Levi, M; Sheiner, LB, 2007
)
0.34
" COT and 3HC saliva concentrations in smokers were simulated utilizing a mechanistic population pharmacokinetic model of NIC metabolism that was adapted from the one described in a companion paper."( Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II. Model application.
Benowitz, NL; Dempsey, DA; Levi, M; Sheiner, LB, 2007
)
0.34
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" However, age-related pharmacokinetic differences may confound the interpretation of these findings."( Nicotine pharmacokinetics in rats is altered as a function of age, impacting the interpretation of animal model data.
Craig, EL; Cui, JZ; Miksys, S; Novalen, M; Tyndale, RF; Zhao, B, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
" Previously reported methodology for determining nicotine bioavailability has been improved by using stable isotope-labeled nicotine administered intravenously."( Recent studies of nicotine metabolism in humans.
Benowitz, NL; Jacob, P; Shulgin, AT, 1988
)
0.27
" This study also validates a recently proposed method for estimating absolute bioavailability of a drug using drug and metabolite pharmacokinetic data, and presents novel data on plasma levels of the metabolite trans-3'-hydroxycotinine in people."( Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking.
Benowitz, NL; Jacob, P; Zevin, S, 1997
)
0.48

Dosage Studied

Cis-3'-Hydroxycotinine was detected as an S(-)-nicotine metabolite in the urine of smokers and rats and hamsters dosed with nicotine. No evidence for a mutagenic activity was found.

ExcerptRelevanceReference
" cis-3'-Hydroxycotinine was detected as an S(-)-nicotine metabolite in the urine of smokers as well as in the urine of rats and hamsters dosed with nicotine."( Identification of cis-3'-hydroxycotinine as a urinary nicotine metabolite.
Rustemeier, K; Schepers, G; Voncken, P, 1990
)
1.02
" This study aimed primarily to assess sources of individual variability in nicotine and metabolite plasma levels from these dosing systems and from cigarette smoking."( Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking.
Benowitz, NL; Jacob, P; Zevin, S, 1997
)
0.3
" To compensate for individual differences in clearance, individualization of nicotine dosing based on therapeutic drug monitoring with comparison to nicotine or continine levels during cigarette smoking prior to treatment may be necessary to optimize nicotine therapy."( Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking.
Benowitz, NL; Jacob, P; Zevin, S, 1997
)
0.3
"We provide novel pharmacokinetic and metabolic data on nicotine after systemic dosing in relation to common CYP2A6 genotypes."( CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.
Benowitz, NL; Jacob, P; Lessov-Schlaggar, CN; Swan, GE; Tyndale, RF, 2006
)
0.33
" Metabolizing enzyme to produce cotinine from nicotine was saturated after multiple oral dosing for 4 weeks in a low dose (1 mg/kg/day), but within 1 week in the dose of 5 and 10 mg/kg/day."( Relations between toxicity and altered tissue distribution and urinary excretion of nicotine, cotinine, and hydroxycotinine after chronic oral administration of nicotine in rats.
Chung, BC; Hong, J; Jung, BH; Kim, KY; Lee, YJ, 2010
)
0.57
" Significant dose-response relationships between most VOC metabolites and 8-OHdG were observed."( Exposure to volatile organic compounds may be associated with oxidative DNA damage-mediated childhood asthma.
Fan, R; Jiang, W; Kuang, H; Li, Y; Li, Z; Lv, X; Pang, Q; Tan, J; Wang, Y; Wu, P; Wu, Q, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (4)

ClassDescription
N-alkylpyrrolidine
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
pyrrolidine alkaloid
pyrrolidin-2-onesA pyrrolidinone in which the oxo group is at position 2 of the pyrrolidine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
nicotine degradation III4326

Bioassays (4)

Assay IDTitleYearJournalArticle
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (192)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (5.73)18.7374
1990's26 (13.54)18.2507
2000's46 (23.96)29.6817
2010's90 (46.88)24.3611
2020's19 (9.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.30 (24.57)
Research Supply Index5.40 (2.92)
Research Growth Index4.99 (4.65)
Search Engine Demand Index42.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.30)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials20 (10.00%)5.53%
Reviews2 (1.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (0.50%)0.25%
Other177 (88.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]